A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel

NCT01251653 · clinicaltrials.gov ↗

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Afatinib
DRUG: Afatinib
DRUG: docetaxel
DRUG: gemcitabine

Sponsor

Boehringer Ingelheim